English  |  正體中文  |  简体中文  |  全文筆數/總筆數 : 12145/12927 (94%)
造訪人次 : 863748      線上人數 : 806
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
搜尋範圍 查詢小技巧:
  • 您可在西文檢索詞彙前後加上"雙引號",以獲取較精準的檢索結果
  • 若欲以作者姓名搜尋,建議至進階搜尋限定作者欄位,可獲得較完整資料
  • 進階搜尋
    主頁登入上傳說明關於NHRI管理 到手機版

    類別瀏覽

    正在載入社群分類, 請稍候....

    年代瀏覽

    正在載入年代分類, 請稍候....

    "Komatsu, Y"的相關文件 

    回到依作者瀏覽

    顯示 9 項.

    類別 日期 題名 關聯 檔案
    [陳立宗] 會議論文/會議摘要 2017-09 Interim safety and clinical activity of nivolumab (Nivo) in combination with S-1/capecitabine plus oxaliplatin in patients (pts) with previously untreated unresectable advanced or recurrent gastric/gastroesophageal junction (G/GEJ) cancer: part 1 study of ATTRACTION-04 (ONO-4538-37) -
    [陳立宗] 期刊論文 2019-02 Safety and efficacy of nivolumab in combination with S-1/capecitabine plus oxaliplatin in patients with previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: Interim results of a randomized, phase II trial (attraction-4) -
    [陳立宗] 期刊論文 2019-03 A subanalysis of Japanese patients in a randomized, double-blind, placebo-controlled, phase 3 trial of nivolumab for patients with advanced gastric or gastro-esophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens -
    [陳立宗] 會議論文/會議摘要 2019-10 Randomised phase 3 study of regorafenib in refractory advanced gastro-oesophageal cancer (AGOC) - Integrate II -
    [陳立宗] 會議論文/會議摘要 2021-07 Primary results of phase 2 FOENIX-CCA2: The irreversible FGFR1-4 inhibitor futibatinib in intrahepatic cholangiocarcinoma (iCCA) with FGFR2 fusions/rearrangements -
    [陳立宗] 會議論文/會議摘要 2021-09 Primary results of phase 2 FOENIX-CCA2: the irreversible FGFR1-4 inhibitor futibatinib in intrahepatic cholangiocarcinoma (iCCA) with FGFR2 fusions/rearrangements -
    [陳立宗] 會議論文/會議摘要 2022-06 Updated results of the FOENIX-CCA2 trial: Efficacy and safety of futibatinib in intrahepatic cholangiocarcinoma (iCCA) harboring FGFR2 fusions/rearrangements -
    [陳立宗] 期刊論文 2023-01-19 Futibatinib for FGFR2-rearranged intrahepatic cholangiocarcinoma -
    [陳立宗] 期刊論文 2024-06-17 Plain language summary of the FOENIX-CCA2 study: Futibatinib for people with advanced bile duct cancer -

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - 回饋